Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleYahoo Finance· March 24, 2026
KELUN-BIOTECH ANNOUNCED 2025 ANNUAL RESULTS: MULTIPLE PRODUCTS SUCCESSFULLY LAUNCHED WITH TIERED PIPELINE READY FOR TAKE-OFF
View original at finance.yahoo.com“Revenue amounted to approximately RMB2057.92 million, and gross profit amounted to approximately RMB1478.78 million, representing a year-on-year increase.”
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The company is gradually expanding into broader non-oncology therapeutic areas such as autoimmune diseases and metabolic disorders
60% confidenceThe company is actively advancing cutting-edge modalities including bispecific ADCs, RDCs, iADCs, and DACs
60% confidenceThe company has built a robust pipeline of more than 30 drug candidates, with over 10 in the clinical stage
60% confidenceThe company will leverage its innovative and differentiated pipeline to deliver high-quality therapeutic solutions for major unmet medical needs worldwide
60% confidence
